Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil

Revista de Saúde Pública

Augusto Afonso Guerra Júnior¹  Grazielle Dias Silva¹  Eli Iola Gurgel Andrade¹  Mariângela Leal Cherchiglia¹  Juliana De Oliveira Costa¹  Alessandra Maciel Almeida¹  Francisco De Assis Acurcio¹ 

关键词: Immunosuppressive Agents;    therapeutic use;    Kidney Transplantation;    economics;    Graft Survival;    Transplantation Tolerance;    drug effects;    Cost-Benefit Analysis;    Unified Health System;    Cohort Studies;    Imunossupressores;    uso terapêutico;    Transplante de Rim;    economia;    Sobrevivência de Enxerto;    Tolerância ao Transplante;    efeitos de drogas;    Análise Custo-Benefício;    Sistema Único de Saúde;    Estudos de Coortes;   

DOI  :  10.1590/S0034-8910.2015049005430

来源: SciELO

【 摘 要 】

OBJECTIVE To analyze the cost-effectiveness of treatment regimens with cyclosporine or tacrolimus, five years after renal transplantation.METHODS This cost-effectiveness analysis was based on historical cohort data obtained between 2000 and 2004 and involved 2,022 patients treated with cyclosporine or tacrolimus, matched 1:1 for gender, age, and type and year of transplantation. Graft survival and the direct costs of medical care obtained from the National Health System (SUS) databases were used as outcome results.RESULTS Most of the patients were women, with a mean age of 36.6 years. The most frequent diagnosis of chronic renal failure was glomerulonephritis/nephritis (27.7%). In five years, the tacrolimus group had an average life expectancy gain of 3.96 years at an annual cost of R$78,360.57 compared with the cyclosporine group with a gain of 4.05 years and an annual cost of R$61,350.44.CONCLUSIONS After matching, the study indicated better survival of patients treated with regimens using tacrolimus. However, regimens containing cyclosporine were more cost-effective.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License